/
enGene Therapeutics (ENGN) generated about $0.00 in revenue and -$127 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
enGene Therapeutics generated about $0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
enGene Therapeutics reported about -$127 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.